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Abstract
Background: There are conflicting and inconsistent results in the literature on the prognostic role of quality of life
(QoL) in cancer. We investigated whether QoL at admission could predict survival in lung cancer patients.
Methods: The study population consisted of 1194 non-small cell lung cancer patients treated at our institution
between Jan 2001 and Dec 2008. QoL was evaluated using EORTC-QLQ-C30 prior to initiation of treatment. Patient
survival was defined as the time interval between the date of first patient visit and the date of death from any
cause/date of last contact. Univariate and multivariate Cox regression evaluated the prognostic significance of QoL.
Results: Mean age at presentation was 58.3 years. There were 605 newly diagnosed and 589 previously treated
patients; 601 males and 593 females. Stage of disease at diagnosis was I, 100; II, 63; III, 348; IV, 656; and 27
indeterminate. Upon multivariate analyses, global QoL as well as physical function predicted patient survival in the
entire study population. Every 10-point increase in physical function was associated with a 10% increase in survival
(95% CI = 6% to 14%, p < 0.001). Similarly, every 10-point increase in global QoL was associated with a 9%
increase in survival (95% CI = 6% to 11%, p < 0.001). Furthermore, physical function, nausea/vomiting, insomnia,
and diarrhea (p < 0.05 for all) in newly diagnosed patients, but only physical function (p < 0.001) in previously
treated patients were predictive of survival.
Conclusions: Baseline global QoL and physical function provide useful prognostic information in non-small cell
lung cancer patients.
Background
Lung cancer is the most common cancer in the United
States in terms of incidence and mortality with 219,440
new cases and 159,390 deaths in 2009 [1]. Patients with
lung cancer experience a variety of distressing symp-
toms, many of which begin prior to diagnosis and con-
tinue throughout the course of the disease and its
treatment, adversely affecting functional status and qual-
ity of life (QoL) [2,3]. The vast majority of patients,
especially those with advanced disease, do not have
curative treatment options and therefore, the goal of
therapy for such patients is prolongation of survival
without negatively impacting QoL [4]. Unfortunately,
differences in survival time across the spectrum of avail-
able treatments for advanced lung cancer are modest.
Thus, treatment for lung cancer which offers the
potential for prolonging patient survival must always be
judged in the context of its effects on patient QoL [5-8].
Since every patient’s QoL is multidimensional, consist-
ing of physical, functional, psychological, social, and
spiritual domains [5], there is a growing consensus that
treatment efficacy should be judged by its effects on
both quantity and quality of life. This has led to the
inclusion of QoL assessment as a primary endpoint in
all types of clinical trials along with the traditional end-
points of tumor response and survival. There is general
agreement in the medical and scientific research com-
munities that patients are the best source of QoL infor-
mation, especially when these patient-reported
outcomes can be defined scientifically and measured
with validated tools.
Extensive data in the literature have shown that QoL
tools measuring the activities of daily life can predict
survival in several different types of cancers independent
of the extent of the disease and other clinical prognostic
factors [9-27]. These studies have used different QoL
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any medium, provided the original work is properly cited.instruments which can be broadly classified into generic
and targeted [28]. Generic QoL instruments tend to ask
questions general enough for broad applicability, includ-
ing for use among individuals in good health. On the
other hand, targeted measures may focus on specific
symptoms that are common to a particular cancer or to
its treatment. There is no “gold standard” cancer QoL
questionnaire available and the choice of selecting a
QoL questionnaire for a particular study is governed for
the most part by the research goals of that study.
The positive relationship between QoL and survival
as described above has not been universally observed
in the literature, with some studies founding no asso-
ciation between QoL and survival [29-31]. As a result,
t h e r ei sn ou n a n i m i t yo nt h ep r o g n o s t i cr o l eo fQ o Li n
cancer. These conflicting and inconsistent results in
the literature could perhaps reflect the different meth-
odologies used to analyze the data (as an example by
selecting different cut off values for variables), different
patient populations investigated, different QoL ques-
tionnaires used, or alternatively, different selection of
covariates to be included in the regression analysis
[32]. Moreover, it is currently unclear why QoL may
be prognostic, and it has been hypothesized that, in
patients with micrometastatic disease, there is produc-
tion of tumor factors that affect general health and
that patients perceive this and report it in terms of
poor QoL before it is clinically or radiologically appar-
ent [33]. Therefore, preclinical progression of disease
after curative treatment may be associated with wor-
sening of QoL, which may be assessed with self-
reported QoL measures [33]. It is possible that QoL
presumably captures those aspects of disease severity
that may not be apparent in the observer-rated perfor-
mance status or tumor burden [34]. In the light of the
above, we investigated whether QoL can predict survi-
val in non-small cell lung cancer patients treated at a
community hospital comprehensive cancer center.
Methods
Study Sample
We examined 1194 histologically confirmed non-small
cell lung cancer patients treated at Cancer Treatment
Centers of America
® (CTCA) at Midwestern (MRMC)
and Southwestern (SRMC) Regional Medical Centers
between Jan 2001 and Dec 2008. None of these patients
had received any treatment at our hospitals when con-
tacted to participate in this investigation. The inclusion
criteria for participation in this study were a histological
diagnosis of lung cancer and the ability to read English.
Patients with all stages of lung cancer were eligible for
the study. Patients were excluded if they were unable to
give informed consent or were unable to understand or
cooperate with study conditions.
A trained clinical coordinator was responsible for
determining eligibility, describing the study, and obtain-
ing informed consent. All patients were assured that
refusal to participate would not affect their future care
in any way. Patients who chose to participate were pre-
sented with the questionnaire at their initial visit and
instructed to return their completed questionnaires to
the clinical coordinator within 24 hours; thus, patients
completed questionnaires prior to receiving therapy at
our facility. Data were systematically collected and
entered in an excel spreadsheet which was maintained
by the Office of Clinical Research. Several quality checks
w e r ep e r f o r m e df r o mt i m et ot i m et oe n s u r ec o m p l e t e -
ness and accuracy of data. QoL data used in this study
is part of a long-term prospective database on QoL in
cancer patients treated at CTCA.
Additional patient data recorded for this study were
gender, age at presentation (current age), stage of dis-
ease at diagnosis and prior treatment history. The only
follow-up information required was the date of death or
the date of last contact/last known to be alive. This
study was approved by the Institutional Review Boards
at MRMC and SRMC.
QoL Assessment
QoL was assessed using European Organization for the
Research and Treatment of Cancer Core Quality of Life
Questionnaire (QLQ-C30), which emphasizes a patient’s
capacity to fulfill the activities of daily living. The QLQ-
C30 is a 30-item cancer specific questionnaire that
incorporates five functioning scales (physical, role, cog-
nition, emotional, and social), nine symptom scales (fati-
gue, pain, and nausea/vomiting, dyspnea, insomnia, loss
of appetite, constipation, diarrhea, financial problems),
and a global health status/QoL scale. The raw scores are
linearly transformed to give standard scores in the range
of 0-100 for each of the functioning and symptom
scales. Higher scores in the global and functioning scales
and lower scores in the symptom scales indicate better
QoL. A difference of 5-10 points in the scores repre-
sents a small change, 10-20 points a moderate change
and greater than 20 points a large clinically significant
change from the patient’s perspective [35]. This instru-
ment has been judged to be reliable and valid as a result
of extensive testing in a wide range of clinical cancer
populations [36-38].
Prespecified Baseline Clinical Factors
Baseline clinical factors that were assessed for prognos-
tic significance were gender, current age, stage of disease
at diagnosis and prior treatment history. Stage at diag-
nosis was categorized into two groups consisting of
locoregional (stages I-III) and metastatic (stage IV) dis-
ease. The prior treatment history variable categorized
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cer treatment elsewhere before coming to our institution
and those who were newly diagnosed at the time of pre-
sentation to our institution. These data were obtained
from the tumor registries of MRMC and SRMC.
Data Analysis and Statistical Methods
Patient survival was the primary end point and
defined as the time interval between the date of first
patient visit to the hospital and the date of death
from any cause or the date of last contact/last known
to be alive. The overall survival was calculated using
the Kaplan-Meier or product-limit method. Clinical
and QoL variables were also evaluated using univari-
ate Cox regression analyses to determine which para-
meters showed individual prognostic value for
survival. Multivariate Cox regression analyses were
then performed to evaluate the joint prognostic signif-
icance of those QoL and clinical factors that were
shown to be prognostic in univariate analyses. We
used both forward stepwise method as well as the
block entry method (all variables entered together at
t h es a m et i m ei no n eb l o c k ) .F o r w a r ds t e p w i s e
method was used because, as is common in QoL data,
many of the individual QoL scales are highly corre-
lated. Stepwise regression avoids the problem of mul-
ticollinearity because two highly correlated attributes
will normally not both be entered in the model. Since
the global QoL scale of the QLQ-C30 is highly corre-
lated with other scales, it was not included in prog-
nostic indicator analyses when other variables from
QLQ-C30 were used, in order to achieve model stabi-
lity [28]. Instead, global QoL was analyzed separately
after adjusting for clinical and demographic factors.
Separate analyses stratified by prior treatment history
were conducted to identify QoL factors prognostic of
survival in both newly diagnosed and previously trea-
ted patients.
Cox regression with time-invariant covariates assumes
that the ratio of hazards for any two groups remains
constant in proportion over time. We checked this
assumption by first examining log-minus-log plots for
the categorical predictors and then fitting a Cox regres-
sion with a time-varying covariate for each predictor in
turn. Each QLQ-C30 scale was treated as a continuous
variable for the purpose of Cox regression analyses. The
effect of QoL parameters on patient survival was
expressed as Hazard Ratios (HRs) with 95% confidence
intervals (CIs). Pearson’s correlation coefficients were
used to investigate the association between different
QoL variables. An effect was considered to be statisti-
cally significant if the p value was less than or equal to
0.05. All data were analyzed using SPSS version 17.0
(SPSS, Chicago, IL, USA).
Results
Patient characteristics
Table 1 describes the baseline characteristics of our
patient cohort while Table 2 provides descriptive statis-
tics for the population from the QLQ-C30 scale scores.
Among the QLQ-C30 functioning scales, role function-
ing had the lowest (worst) mean score of 58.9 while the
h i g h e s t( b e s t )m e a ns c o r eo f7 4 . 9w a sr e c o r d e df o rc o g -
nitive functioning. Among the QLQ-C30 symptom
scales, diarrhea had the lowest (best) mean score of 9.9
while the highest (worst) mean score of 46.8 was
recorded for fatigue.
Relationship between QoL and other covariates
Table 3 describes the distribution of QoL scores by
stage of disease and prior treatment history using 2
Table 1 Baseline characteristics of 1194 lung cancer
patients
Characteristic Categories Number Percent
Age at presentation (years) ■ Mean 58.3
■ Median 58.5
■ Range 21.6-86.4
Gender ■ Male 601 50.3
■ Female 593 49.7
Tumor Stage at Diagnosis ■ Stage 1 100 8.4
■ Stage 2 63 5.3
■ Stage 3 348 29.1
■ Stage 4 656 54.9
■ Indeterminate 27 2.3
Vital Status ■ Expired 778 65.2
■ Alive 416 34.8
Treatment History ■ Newly diagnosed 605 50.7
■ Previously treated 589 49.3
Table 2 Baseline QoL scores of 1194 lung cancer patients
QLQ-C30 Scale Mean Median SD Range
Global 53.6 58.3 26.3 0-100
Physical 68.7 73.3 25.5 0-100
Role 58.9 66.7 34.3 0-100
Emotional 64.1 66.7 25.8 0-100
Cognitive 74.9 83.3 25.9 0-100
Social 61.2 66.7 32.9 0-100
Fatigue 46.8 44.4 28.4 0-100
Nausea/Vomiting 14.5 0 22.2 0-100
Pain 37.1 33.3 32.8 0-100
Dyspnea 37.6 33.3 33.6 0-100
Insomnia 39.9 33.3 33.5 0-100
Appetite Loss 31.3 33.3 34.1 0-100
Constipation 24.2 0 31.3 0-100
Diarrhea 9.9 0 19.7 0-100
Higher scores in the global and functioning scales and lower scores in the
symptom scales indicate better QoL.
Braun et al. BMC Cancer 2011, 11:353
http://www.biomedcentral.com/1471-2407/11/353
Page 3 of 9sample t-tests. Mean global QoL scores were 53.8 and
53.1 for locoregional and metastatic disease (p = 0.63)
and 56.1 and 50.9 for newly diagnosed and previously
treated disease respectively (p = 0.001). Fatigue and pain
scores were significantly higher (poorer) in patients with
metastatic disease as compared to those with locoregio-
nal disease. Similarly, physical, role and social function-
ing scores and fatigue, nausea/vomiting, pain, dyspnea
and appetite loss symptom scores were significantly
poorer in previously treated patients as compared to
newly diagnosed patients. We also evaluated the rela-
tionship between QoL and age at presentation using
Pearson correlation (r). The function scales to be signifi-
cantly correlated with age were physical (r = -0.06; p =
0.04), emotional (r = 0.07; p = 0.01) and social (r = 0.07;
p = 0.01). Physical scale was negatively correlated (such
that higher age was associated with a poorer physical
function) while emotional and social scales were posi-
tively correlated (such that higher age was associated
with better emotional and social functions). Among the
symptom scales, nausea/vomiting (r = -0.09; p = 0.001),
pain (r = -0.16; p = 0.001) and insomnia (r = -0.12; p =
0.001) were negatively correlated with age (such that
higher age was associated with better nausea/vomiting,
pain and insomnia) while dyspnea (r = 0.08; p = 0.007)
was positively correlated (such that higher age was asso-
ciated with poorer dyspnea). All these correlations were
very weak (with r less than 0.20 in either direction).
Univariate analysis: prognostic factors for overall survival
Median overall survival for the entire patient cohort was
8.8 months (95% CI: 8.0-9.5 months). The median survi-
val for newly diagnosed and previously treated patients
was 12.6 and 6.8 months respectively, p < 0.001. The
median survival for patients with locoregional and meta-
static disease was 12.0 and 7.5 months respectively, p <
0.001. Table 4 describes the results of univariate Cox
regression analyses for each QLQ-C30 scale as well as
age, stage of disease and prior treatment history. The
HRs along with their 95% CIs for every one-unit
increase in all QLQ-C30 scales are given. On univariate
analysis, QoL scales predictive of survival were global (p
< 0.001), physical (p < 0.001), role (p < 0.001), emotional
(p = 0.04), cognitive (p = 0.003), social (p < 0.001), fati-
gue (p < 0.001), nausea/vomiting (p = 0.001), pain (p <
0.001), dyspnea (p < 0.001), loss of appetite (p < 0.001),
constipation (p = 0.001) and diarrhea (P = 0.02). Gen-
der, stage of disease at diagnosis and prior treatment
history were also found to be significant predictors of
survival upon univariate analysis (p < 0.001 for all).
Multivariate analysis: prognostic factors for overall
survival
Table 5 describes the results of multivariate Cox regres-
sion analyses using the block entry method for those
QLQ-C30 function and symptom scales that were signif-
icant upon univariate analysis after controlling for the
effects of gender, tumor stage and prior treatment his-
tory. Upon multivariate analyses, only physical function
(p < 0.001) was predictive of survival independent of
other QoL scales, gender, stage, and treatment history.
Every 10-point increase in physical function was asso-
ciated with a 10% increase in survival (95% CI = 6% to
14%, p < 0.001). Gender, stage of disease and prior
treatment history were also found to be significant pre-
dictors in the final multivariate model (p < 0.01 for all).
Table 3 Distribution of QoL scores by stage of disease and prior treatment history
QLQ-C30 Scale Stage of disease Treatment History
Locoregional
(N = 511)
Metastatic
(N = 656)
P Newly diagnosed
(N = 605)
Previously treated
(N = 589)
P
Global 53.8 53.1 0.63 56.1 50.8 0.001
Physical 69.4 68.0 0.35 73.1 64.1 < 0.001
Role 60.4 57.2 0.12 62.4 55.2 < 0.001
Emotional 64.5 63.5 0.55 63.3 64.8 0.33
Cognitive 75.1 74.5 0.68 75.9 73.7 0.16
Social 62.0 60.2 0.35 65.3 56.8 < 0.001
Fatigue 45.0 48.6 0.03 43.1 50.6 < 0.001
Nausea/Vomiting 13.9 15.1 0.36 12.2 16.8 < 0.001
Pain 34.7 39.0 0.02 34.0 40.3 0.001
Dyspnea 39.5 36.0 0.08 34.7 40.6 0.002
Insomnia 39.0 41.0 0.31 40.5 39.3 0.54
Appetite Loss 30.2 32.3 0.29 28.4 34.1 0.004
Constipation 22.7 25.4 0.14 23.2 25.2 0.27
Diarrhea 9.9 9.8 0.92 8.8 10.9 0.07
Higher scores in the global and functioning scales and lower scores in the symptom scales indicate better QoL.
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forward stepwise method. It was interesting to see that
most of the function and symptom scales that were pre-
dictive of survival upon univariate analysis lost their sta-
tistical significance upon multivariate analysis. This is
not an uncommon observation in QoL analyses, because
many of the individual QoL scales are highly correlated
with each other, and therefore lose their statistical sig-
nificance when analyzed together.
Table 6 describes the results of multivariate Cox
regression analyses using the block entry method for
global QoL after controlling for the effects of gender,
tumor stage and prior treatment history. Every 10-point
increase in global QoL was associated with a 9%
increase in survival (95% CI = 6% to 11%, p < 0.001).
Gender, stage of disease and prior treatment history
were also found to be significant predictors in the final
multivariate model (p < 0.01 for all).
Discussion
Even though the QoL of patients is considered a critical
endpoint in oncology that can also provide useful prog-
nostic information to patients and clinicians, QoL con-
tinues to be evaluated infrequently in most clinic
oncology practices apart from research studies. The bar-
rier is not a lack of valid tools but rather the challenges
Table 4 Univariate Cox regression analysis for overall survival
QoL Domain HR 95% CI P-value
Global 0.991 0.989 to 0.994 < 0.001
Physical 0.988 0.985 to 0.990 < 0.001
Role 0.993 0.991 to 0.995 < 0.001
Emotional 0.997 0.994 to 1.00 0.04
Cognitive 0.996 0.993 to 0.999 0.003
Social 0.994 0.992 to 0.996 < 0.001
Fatigue 1.009 1.006 to 1.011 < 0.001
Nausea/vomiting 1.005 1.002 to 1.008 0.001
Pain 1.006 1.004 to 1.009 < 0.001
Dyspnea 1.005 1.003 to 1.008 < 0.001
Insomnia 1.000 0.998 to 1.003 0.66
Appetite Loss 1.006 1.004 to 1.008 < 0.001
Constipation 1.004 1.002 to 1.006 0.001
Diarrhea 1.004 1.001 to 1.008 0.02
Age at presentation 0.998 0.991 to 1.006 0.65
Gender (male as reference) 0.77 0.67 to 0.89 < 0.001
Stage at diagnosis (locoregional disease as reference) 1.57 1.4 to 1.8 < 0.001
Prior treatment history (previously treated as reference) 0.55 0.48 to 0.64 < 0.001
Table 5 Multivariate Cox regression analysis for QoL function and symptom scales (Block Entry Method)
QoL Domain HR 95% CI P-value
Physical 0.990 0.986 to 0.994 < 0.001
Role 0.999 0.995 to 1.002 0.50
Emotional 1.001 0.997 to 1.005 0.58
Cognitive 1.000 0.996 to 1.003 0.80
Social 1.000 0.996 to 1.003 0.85
Fatigue 0.996 0.992 to 1.001 0.16
Nausea/vomiting 0.997 0.993 to 1.001 0.20
Pain 1.002 0.999 to 1.005 0.16
Dyspnea 1.001 0.999 to 1.004 0.34
Appetite Loss 1.003 1.000 to 1.005 0.07
Constipation 1.000 0.998 to 1.003 0.73
Diarrhea 1.003 0.999 to 1.006 0.16
Gender (male as reference) 0.78 0.67 to 0.90 0.001
Stage at diagnosis (locoregional disease as reference) 1.67 1.4 to 1.9 < 0.001
Prior treatment history (previously treated as reference) 0.55 0.47 to 0.64 < 0.001
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clinical practices [5]. This will continue as long as QoL
assessment is regarded as peripheral to the goal of stan-
dard clinical cancer therapy. It is our contention, how-
ever, that QoL is as meaningful to patients as length of
life, a situation which is coming to be appreciated by
patients, advocates, insurance providers, and employers.
Thus, there is a strong rationale to incorporate regular
QoL assessment and management into all oncologic
practice settings.
I nt h ec u r r e n ts t u d y ,w ec h o s eQ L Q - C 3 0a sav a l i d
and reliable tool to assess patient QoL which is appro-
priate for assessing large, heterogeneous patient popula-
tions. It is relevant that this instrument concentrates on
ap a t i e n t s ’ ability to fulfill the activities of daily living.
While this emphasis has been regarded in research stu-
dies as an appropriate way to assess the effectiveness of
new drugs or novel combinations of agents, cumulative
experience from several decades of use of the QLQ-C30
also demonstrate the relevance of this information for
clinical practitioners. Thus, results from the QLQ-C30
provide important information to guide treatment deci-
sions based on balancing the need to control tumor pro-
gression with the need to know how treatment affects
the patient’s capacity to fulfill the activities of their daily
life at work and in the home.
In this study, we found that global QoL as well as
physical function were significant predictors of patient
survival in the entire study population. The finding of
physical function predicting survival in lung cancer has
been reported by previous studies [11,20,39-41]. For
example, Ganz et al. reported a statistically significant
relationship between initial patient-rated QoL scores
and subsequent survival [40]. In another study by Hern-
don et al., increased pain, appetite loss, fatigue, lung car-
cinoma symptoms, poorer overall QoL, and poorer
physical functioning predicted significantly poorer survi-
val. However, only the pain score was retained in the
final multivariate model [20]. Finally, a study conducted
by Fielding and Wong found that better physical func-
tioning and better appetite were predictive of longer
survival after fully adjusting for sociodemographic and
clinical factors in Chinese lung cancer patients [39].
The finding of global QoL predicting survival in lung
cancer has also been reported by previous studies
[15,20,22,25,41-43]. For example, Langendijk et al.
examined the significance of pretreatment QoL and
symptom scores in lung cancer patients treated with
high dose radiotherapy and found the EORTC global
QoL score as the strongest prognostic factor [22]. Mon-
tazeri et al. showed that pre-diagnosis EORTC global
QoL was a significant predictor of survival in lung can-
cer [25]. Dharma-Wardene et al. found that baseline
FACT-G total score is a statistically significant predictor
of survival in patients with advanced lung cancer [15].
Brown et al. found EORTC global QoL, role functioning,
fatigue, appetite loss, and constipation as prognostic
indicators of survival in patients with NSCLC at 12
w e e k s[ 4 2 ] .M a i o n ee ta l .f o u n dt h a to n l yp r e t r e a t m e n t
EORTC global QoL and instrumental activities of daily
living scores were significant predictors for survival in
elderly patients with advanced non-small-cell lung can-
cer treated with chemotherapy [43].
In the previously published studies mentioned above,
the most commonly adjusted variables were age, gender,
socioeconomic status, performance status, various cell
counts, metastasis, treatment types, cancer stage, histol-
ogy subtypes, sites involved, and weight loss. However,
it is worth mentioning that some of these studies failed
to provide adequate controls for confounding, for exam-
ple, there is no information on the extent of the disease
or whether the tumor size shrank in response to therapy
[15,22,32]. In most of these studies, it is not possible to
determine whether QoL independently predicted survi-
val or simply reflected the progress of the underlying
disease. For example, it has been suggested that physical
functioning might be a surrogate marker for an unrec-
ognized biological prognostic indicator, so a causal asso-
ciation between physical functioning and survival time
should not be inferred [28].
It is to be noted that in our study, several QoL func-
tion and symptom scales that were predictive of survival
on univariate analysis, lost their statistical significance
after the basic demographic and clinical factors were
adjusted for. Only physical and global function retained
their statistical significance in multivariate modeling.
Collectively, these results demonstrate that after the
potential confounding factors are adjusted for in the
multivariate analysis, the prognostic effects of QoL
either disappear or are mitigated significantly. Thus,
before making any claims regarding the independent
prognostic effects of QoL in cancer, adequate statistical
Table 6 Multivariate Cox regression analysis for global QoL (Block Entry Method)
QoL Domain HR 95% CI P-value
Global 0.991 0.989 to 0.994 < 0.001
Gender (male as reference) 0.78 0.68 to 0.91 0.001
Stage at diagnosis (locoregional disease as reference) 1.72 1.5 to 1.9 < 0.001
Prior treatment history (previously treated as reference) 0.52 0.45 to 0.61 < 0.001
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our finding on global function should be interpreted
with caution because the global function score likely
reflects the contribution of the physical function score.
We also found that physical function, nausea/vomit-
ing, insomnia, and diarrhea in newly diagnosed patients
predicted survival in multivariate analysis. Similarly, in
previously treated patients, physical function was predic-
tive of survival in multivariate analysis. For both of
these clinical settings, it is easy to appreciate the nega-
tive impact these attributes would exert on the ability of
a patient to function. While the current study does not
elucidate causative relationships between these functions
and patient survival, the importance of measuring these
functions in patients and attempting to address their
effects therapeutically should be obvious. The finding of
poorer physical, role and social functioning scores and
fatigue, nausea/vomiting, pain, dyspnea and appetite loss
symptom scores in previously treated patients as com-
pared to newly diagnosed patients is not surprising
given that previously treated patients have more
advanced disease and are well into their course of illness
as compared to newly diagnosed patients.
The results of this study have important implications
for both clinical and research practices in an integrative
oncologic care setting. They suggest that health care
professionals should evaluate baseline QoL in all
patients and take this into consideration when planning
treatment. QoL should also be assessed regularly during
treatment and appropriate intervention taken to improve
QoL when indicated. QoL was initially designed to be
used as a clinical indicator. Self-reported QoL assess-
ment using validated questionnaires plays a very impor-
tant role in acquiring and monitoring information on
patient’s functional and symptom status throughout the
course of treatment. In the absence of concrete informa-
tion on the prognostic role of QoL in cancer survival, its
utility as a clinical indicator should not be jeopardized.
In fact, information about QoL in lung cancer patients
undergoing treatment can provide healthcare providers
with a perspective on post-treatment recovery, including
the positive aspects of long-term care, as well as antici-
pated problems [3].
Although this study presents interesting findings and
additional questions for further inquiry, several limita-
tions require acknowledgment. Our study, because of its
retrospective nature, relies on data not primarily meant
for research. As a result, we could not control for some
additional factors in our analyses that could influence
survival such as medical comorbidities, performance sta-
tus, socioeconomic factors, support system, exercise,
insurance coverage, employment and educational level.
It has been suggested that QoL data might be markers
of the socioeconomic status of cancer patients. For
instance, cancer patients with higher social class would
have a better QoL, and consequently those who report a
better QoL at baseline assessment may live longer [28].
As suggested by Fielding and Wong, full adjustment is
needed for factors affecting outcome in order to demon-
strate any independent predictive power of QoL [39].
The patient cohort was limited only to those patients
who were English speakers and therefore is not repre-
sentative of the complete spectrum of lung cancer
patients. A majority of our patients had advanced stage
disease at presentation. As a result, generalizability of
the study findings to NSCLC patients with early stage
disease might be questionable. However, we have no
reasons to believe that patients with early stage disease
will have different findings. Moreover, this study is not
able to reveal causative relationships between any QoL
element and patient survival. Rather, QoL was found to
act as a surrogate marker for otherwise undetected
prognostic factors [11]. We did not control for the mul-
tiple comparisons made in this study, but this is accep-
table for hypothesis-generating studies [26]. Finally, we
did not evaluate the prognostic significance of changes
in QoL scores during the entire duration of treatment.
Nevertheless, this study also has several strengths,
including a large sample size; complete data for all
QLQ-C30 subscales for the entire study sample; high
compliance with completion of the questionnaire; the
use of a valid and reliable QoL instrument; comprehen-
sive documented clinical parameters in nearly all
patients; and availability of mature and reliable survival
data.
Conclusions
This study suggests that baseline global QoL and physi-
cal function scale provide useful prognostic information
in non-small cell lung cancer patients.
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